Single-use Bioreactors Market Valued At ~$3.39 Billion In 2021 And Is Expected To Grow At A Cagr Of 20% By 2026

By Author: Tejashri
Total Articles: 61
Comment this article

The Global Single-use Bioreactors Market valued at ~$3.39 billion (2021) is set to witness a healthy growth rate of 20% in the next 5 years. The introduction of large-scale single-use bioreactors, rising demand from pharma companies, CROs, and CDMOs, the expanding biologics market, rising biopharmaceutical R&D, and the advantages of single-use bioreactors are some of the technological advancements that are propelling the global single-use bioreactors market.

Due to their Ability to Enhance Flexibility, Reduce Investment & Limit Operational Costs, Single-use Bioreactors Have Become Established in Modern Biopharmaceutical Processes

One of the main advantages of single-use bioreactors is their increased flexibility. There is a growing trend towards multi-drug facilities, which warrants the production of different drugs using the same facility with minimum time & cost and top-notch quality. Line clearance and cleaning validation in such circumstances are key manufacturing challenges to guarantee there is no carryover from previous batches. Downtime limits the number of batches produced in a given period.

Single-use ...
... bioreactors significantly lessen the amount of time required to get the bioreactor prepared for the subsequent batch. A line changeover with a stainless-steel bioreactor can take ~6 to 10 hours and three weeks for a full product changeover while by using single-use bioreactors it is likely to take 2 hours for line changeover. If the manufacturing line is composed of all single-use components such as bags, filters, and connectors, the total time for product changeover can be 48 hours. Single-use bioreactors may cut downtime from two to three weeks to just 48 hours, which can have a big influence on a company's output.

Some of the other key advantages of using single-use bioreactors are:

Elimination of validation issues as no cleaning process is required
Lowers the risk of cross-contamination
Reduces operating costs and capital investments (including space, labor requirements, and utilities)
Single-use bags are scalable and can be adjusted to different volumes
Simple installation
Potential Time Savings for Highly Trained Personnel Another Key Benefit of Single-use Bioreactors

Normally, drug development research, process development, and scale-up activities are performed by highly qualified and trained personnel. These individuals are involved in all phases of a study from early-stage research through to benchtop manufacturing. Before each trial batch is taken, stainless steel or glass benchtop bioreactors' individual components must be cleaned, put together, tested for leaks, sterilised, and cooled. However, the use of single-use bioreactors almost eliminates these steps, which allows scientists more time to focus on their developmental studies.

Explore Premium Report on Single-use Bioreactors Market @ https://meditechinsights.com/single-use-bioreactors-market/

Technological Advancements & Customer-Centric Approach – A Key Factor Bolstering the Single-use Bioreactors Market Demand

Commercially available single-use bioreactors are robust and provide the high-performance necessary for commercial manufacturing of biopharmaceuticals. The growing usage of single-use bioreactors from the lab to the production scale has been facilitated by significant developments in bioreactor design, film technologies, stirring mechanisms, and sensor systems. To cater to the changing needs of the customers such as next-generation cell- and gene-therapies and continuous bioprocessing, suppliers of single-use bioreactors often work closely with its customers, which in turn is expected to fuel the demand for single-use bioreactors.

“The uptake of single-use bioreactors is mainly driven by the activity of the different regions regarding the development of new disease treatments and biosimilars. In addition, existing production capacity comes into play and company strategies regarding the manufacture of clinical material. As the USA is indeed leading in the field of developing innovative treatments, we see a strong uptake of single-use bioreactors, but Europe and Asia are not far behind.” - CEO, Leading Manufacturer of Single-use Bioreactors, United States

Introduction of Large-Scale Single-use Bioreactors Set to Drive the Single-use Bioreactors Market

Traditionally, single-use bioreactors were restricted in size due to pressure challenges from the increased weight of the liquid medium in larger volume bags with 2,000 L being the upper limit. As a result, bio manufacturers who required higher volumes had to use stainless steel tanks or run multiple systems simultaneously.

However, in the last years, considering strong demand from pharmaceutical companies and contract development and manufacturing organizations (CDMOs), numerous single-use bioreactor manufacturers have launched large-scale single-use bioreactors which are anticipated to drive the market growth in the coming years.

Aligned with this trend in March 2021, Thermo Fisher launched 3,000 L and 5,000 L HyPerforma DynaDrive single-use bioreactors. It is touted as next-level innovation in single-use bioreactors with unmatched design, scalability, and performance. The system provides improved performance and scalability to larger volumes and is suitable for fed-batch and perfusion processes.

Competitive Landscape Analysis of Single-use Bioreactors Market
Some of the key players operating in the global single-use bioreactors market are Sartorius Stedim Biotech, Thermo Fisher Scientific, Danaher Corporation, and Merck KGaA.

Other Players Operating in the Single-use Bioreactors Market are (Indicative List):

ABEC
Cellexus
Celltainer Biotech BV
Distek Inc.
G&G Technologies Inc.
GPC Bio, among others

For More Detailed Insights, Contact Us @ https://meditechinsights.com/contact-us/

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com